Article
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.
Journal for immunotherapy of cancer - 1 Apr 2021
Beyranvand Nejad Elham, Labrie Camilla, van Elsas Marit J, Kleinovink Jan Willem, Mittrücker Hans-Willi, Franken Kees L M C, Heink Sylvia, Korn Thomas, Arens Ramon, van Hall Thorbald, van der Burg Sjoerd H
Abstract excerpt
BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS: IL-6 and IL-6R blockade was applied in an IL-6-mediated immunotherapy-resistant TC-1 tumor model (TC-1.IL-6) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
